Canada’s Cameron Clokie Is Changing the Future of Bone Regeneration in Canada
Cameron Clokie is a renowned Oral and Maxillofacial Surgeon, and also works as a professor of Oral and Maxillofacial Surgery at the University of Toronto. His interest in bone regeneration has seen him publish numerous papers and deliver presentations at national and international platforms on bone reconstruction and restoration. Mr. Clokie is also the CEO of Induce Biologics Inc. and received his Doctor of Dental Surgery (DDS) in 1985 and a doctorate in bone regeneration at the McGill University in 1992.
Regenerative medicine has gained popularity with blood transfusion, bone marrow transplants and cell therapy on burn victims taking the lead. However, scientists are yet to produce mainstream solutions for the treatment of chronic conditions. Majority of the clinical projects lack efficacy and are expensive, hence the high costs of treatment. Mr. Clokie’s experience has seen him spread his knowledge to students, and now to patients after the establishment of Induce Biologics Inc. The technology involves the use of a protein that stimulates the change of adult stem cells into bone.
Through Induce Technologies, Cameron Clokie hopes to reduce the costs of bone regeneration through more research. While he has successfully enabled jawbone regeneration for a few patients, more research into the production of BMP is still ongoing. Bone Morphogenetic Protein (BMP) was discovered in the 1950’s by Marshall Urist, and Mr. Clokie had the opportunity to study under him. The protein has the power to affect stem cells, even in adults and enable the growth of various human tissue types. Currently, Clokie is working towards the production of larger quantities on BMP through goat’s milk, instead of acquiring it from other sources. He believes that the step could significantly reduce the costs of bone regeneration and make it affordable for more people.
Induce Technologies Inc. is currently using URIST™, the lead product that contains a carrier and BMP. The carrier provides a continuous multi-phase delivery of BMP, thus allowing lower dosages of BMP to the body. Lower dosages lower the costs of the treatment and also overcome the toxicity and adverse effects associated with high dosages of BMP. Hopefully, Cameron Clokie’s efforts will yield cost-effective solutions for bone regeneration, and also pave the way for further research in the future.